Leqembi® sales reaches €200 million - first sales milestone achieved

STOCKHOLM, Feb. 18, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached €200 million in Eisai fiscal year 2024 (April 2024 - Match 2025). The event entitles BioArctic to a €10 million payment.  Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally develop ...